Profile data is unavailable for this security.
About the company
SHAANXI KANGHUI PHARMACEUTICAL CO., LTD. is principally engaged in research and development, manufacture and sales of Chinese patent medicines. The Company's main products include Kun Fu Kang capsules (tablets), Fufang Shuanghua tablets, Xiaoyin granules, Fuguigutong capsules, Zhiyao Xiaoke capsules and Fufang Qingdai perfusates. The Company distributes its products just within China domestic market.
- Revenue in CNY (TTM)605.28m
- Net income in CNY-73.67m
- Incorporated2009
- Employees952.00
- LocationShaanxi Kanghui Pharmaceutical Co LtdNo. 36 Yanzhi Road, Qindu DistrictXIANYANG 712000ChinaCHN
- Phone+86 2 933347561
- Fax+86 2 933347561
- Websitehttp://www.sxkh.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hangzhou Tianmushan Phrmtcl ntrprs C Ltd | 160.35m | -14.51m | 1.14bn | 380.00 | -- | 34.23 | -- | 7.14 | -0.1192 | -0.1192 | 1.32 | 0.2746 | 0.4537 | 2.29 | 3.43 | 421,978.40 | -4.39 | -6.93 | -22.04 | -18.92 | 36.69 | 33.95 | -9.69 | -16.42 | 0.4497 | -1.95 | 0.6938 | -- | 11.82 | -19.42 | 43.35 | -- | -24.89 | -- |
| Shaanxi Kanghui Pharmaceutical Co Ltd | 605.28m | -73.67m | 1.59bn | 952.00 | -- | 1.75 | -- | 2.63 | -0.7376 | -0.7376 | 6.06 | 9.12 | 0.292 | 1.86 | 2.74 | 635,795.70 | -4.81 | -0.1562 | -7.31 | -0.1991 | 27.93 | 40.00 | -16.47 | -0.4907 | 0.8304 | -0.9527 | 0.4169 | 95.15 | 36.92 | 12.37 | 58.52 | -- | 66.95 | -- |
| Jiangsu gdk Biotechnology Co Ltd | 52.65m | -113.37m | 1.88bn | 451.00 | -- | 1.43 | -- | 35.80 | -0.9188 | -0.9188 | 0.427 | 10.69 | 0.0321 | 0.4049 | 0.5195 | 116,733.70 | -6.92 | 3.30 | -8.09 | 4.84 | 51.66 | 75.56 | -215.35 | 12.58 | 2.67 | -- | 0.0433 | 32.60 | -57.74 | -- | -270.88 | -- | 54.07 | -- |
| Qinghai Spring Medicinl Rsrcs Tech CoLTD | 251.20m | -287.99m | 1.93bn | 173.00 | -- | 1.69 | -- | 7.67 | -0.4915 | -0.4915 | 0.4298 | 1.94 | 0.1843 | 0.5809 | 4.25 | 1,452,016.00 | -21.01 | -11.25 | -21.83 | -11.55 | 40.40 | 23.44 | -113.97 | -129.81 | 7.06 | -0.9897 | 0.0114 | -- | 33.52 | -8.48 | 6.85 | -- | -20.83 | -- |
Data as of Nov 15 2024. Currency figures normalised to Shaanxi Kanghui Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
0.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Lion Fund Management Co., Ltd.as of 30 Jun 2024 | 31.50k | 0.06% |
| Fortune & Royal Asset Management Co., Ltd.as of 30 Jun 2024 | 17.40k | 0.03% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 3.30k | 0.01% |
| Orient Fund Management Co., Ltd.as of 30 Jun 2024 | 2.60k | 0.01% |
| Nuode Asset Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| Maxwealth Fund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| Tebon Fund Management Co. Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
